Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria.
Reads0
Chats0
TLDR
Inhibition of angiotensin converting enzyme prevents development of nephropathy in normotensive diabetics with persistent microalbuminuria and may be due to reduction in intraglomerular pressure and to prevention of increased systemic blood pressure.Abstract:
STUDY OBJECTIVE--To assess the effectiveness of inhibition of angiotensin converting enzyme in preventing diabetic nephropathy. DESIGN--Randomised follow up study of normotensive diabetics with persistent microalbuminuria (30-300 mg/24 hours) treated with enalapril or its matched placebo for one year. Double blind for first six months, single blind for last six months. SETTING--Diabetic clinic in tertiary referral centre. PATIENTS--Treatment group and placebo group each comprised 10 normotensive diabetics with persistent microalbuminuria. INTERVENTIONS--Treatment group was given enalapril 20 mg daily and controls matched placebo. Patients were given antihypertensive treatment after one year. END POINT--Albumin excretion, arterial pressure, and renal function. MAIN RESULTS--In last three months of trial three of 10 patients taking placebo had diabetic nephropathy (albumin excretion greater than 300 mg/24 hours). No patients taking enalapril developed nephropathy and five showed normal albumin excretion (less than 30 mg/24 hours) (p = 0.005, Mann-Whitney test). Mean arterial pressure was reduced by enalapril throughout study (p less than 0.005) but increased linearly with placebo (p less than 0.05). Albumin excretion decreased linearly with enalapril but not placebo. An increase in albumin excretion with placebo was positively related to the increase in mean arterial pressure (r = 0.709, p less than 0.05, Spearman's rank test). With enalapril total renal resistances and fractional albumin clearances improved progressively (time effect, p = 0.0001). CONCLUSION--Inhibition of angiotensin converting enzyme prevents development of nephropathy in normotensive diabetics with persistent microalbuminuria. This may be due to reduction in intraglomerular pressure and to prevention of increased systemic blood pressure. Future studies should compare long term effects of inhibitors of converting enzyme with other antihypertensive drugs.read more
Citations
More filters
Journal ArticleDOI
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group
TL;DR: Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood-pressure control alone.
Journal ArticleDOI
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
TL;DR: Whether captopril has kidney-protecting properties independent of its effect on blood pressure in diabetic nephropathy is determined.
Journal Article
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
M R Stearne,S L Palmer,M S Hammersley,S L Franklin,R S Spivey,Jonathan C. Levy,C R Tidy,N J Bell,J Steemson,B A Barrow,R Coster,K Waring,L Nolan,E Truscott,N Walravens,B L Cook,H Lampard,C Merle,P Parker,J McVittie,I Draisey,L E Murchison,A H E Brunt,M J Williams,D W Pearson,X M P Petrie,M E J Lean,D Walmsley,F Lyall,E Christie,J Church,E Thomson,A Farrow,J M Stowers,M Stowers,K McHardy,N Patterson,Alex D. Wright,N A Levi,Aci Shearer,R J W Thompson,G Taylor,S Rayton,M Bradbury,A Glover,A Smyth-Osbourne,C Parkes,J Graham,P England,S Gyde,C Eagle,B Chakrabarti,Josh Smith,J Sherwell,E M Kohner,A Dornhorst,M C Doddridge,M Dumskyj,S Walji,P Sharp,M Sleightholm,G Vanterpool,C Rose,G Frost,M Roseblade,S Elliott,S Forrester,Meredith C. Foster,K Myers,R Chapman,J R Hayes,T W Henry,M S Featherston,G P R Archbold,M Copeland,R Harper,I Richardson,S Martin,H A Davison,D R Hadden,L Kennedy,A B Atkinson,A M Culbert,C Hegan,H Tennet,N Webb,I Robinson,J Holmes,P M Bell,D R McCance,J Rutherford,S Nesbitt,A S Spathis,S Hyer,M E Nanson,J M James,J M Tyrell,C Davis,P Strugnell,M Booth,H Petrie,D Clark,B Rice,S Hulland,J L Barron,J S Yudkin,B J Gould,J Singer,A Badenock,M Eckert,K Alibhai,E Marriot,Christopher E. Cox,R Price,M Fernandez,A Ryle,S Clarke,G Wallace,E Mehmed,S MacFarlane,R H Greenwood,James G. Wilson,M J Denholm,R C Temple,K Whitfield,F Johnson,C Munroe,S Gorick,E Duckworth,M Flatman,S Rainbow,L J Borthwick,D J Wheatcroft,R J Seaman,R A Christie,W Wheatcroft,P Musk,Jennifer White,S McDougal,M Bond,P Raniga,R W Newton,R T Jung,C Roxburgh,B Kilgallon,L Dick,N Waugh,S Kilby,A Ellingford,J Burns,C Fox,M C Holloway,H M Coghill,N Hein,A J Fox,W Cowan,M Richard,K Quested,S J Evans,Richard B Paisey,N P R Brown,A J Tucker,R Paisey,F Garrett,J Hogg,P Park,K Williams,P Harvey,R Wilcocks,S Mason,J. C. Frost,C Warren,P Rocket,L Bower,J M Roland,D J Brown,J Youens,K Stanton-King,H Mungall,W Maddison,D Donnelly,S King,P Griffin,Sidney C. Smith,S Church,Graham Dunn,Andrew D. Wilson,K Palmer,P M Brown,D Humphriss,A J M Davidson,Richard Rose,L Armistead,S Townsend,P Poon,I D A Peacock,N J C Culverwell,M H Charlton,B P S Connolly,J Peacock,J Barrett,J Wain,W Beeston,George L. King,P G Hill,A J M Boulton,A M Robertson,Katoulis,A Olukoga,H McDonald,S Kumar,F Abouaesha,B Abuaisha,E A Knowles,S Higgins,J Booker,J Sunter,K Breislin,R Parker,P Raval,J Curwell,H Davenport,G Shawcross,A Prest,J Grey,H Cole,C Sereviratne,R J Young,Tim Dornan,J R Clyne,M Gibson,I O'Connell,L M Wong,S J Wilson,K L Wright,Chris Wallace,D McDowell,A C Burden,E M Sellen,R Gregory,M Roshan,N Vaghela,M Burden,C Sherriff,J Clarke,J Grenfell,Je Tooke,K. M. MacLeod,C Searnark,M Rammell,C Pym,J Stockman,C Yeo,J Piper,L Leighton,Ellen Green,M Hoyle,K Jones,A Hudson,A J James,Angela C. Shore,A Higham,B Martin +262 more
TL;DR: This study provided no evidence that either drug has any specific beneficial or deleterious effect, suggesting that blood pressure reduction in itself may be more important than the treatment used.
Journal ArticleDOI
Long-term complications of diabetes mellitus
TL;DR: Retinopathy is so characteristic of diabetes that its presence has been incorporated into the nosologic definition of NIDDM, while lower levels of hyperglycemia that are of sufficient magnitude to be associated with retinopathy are classified as NID DM.
Journal ArticleDOI
A Comparison of Outcomes With Angiotensin-Converting--Enzyme Inhibitors and Diuretics for Hypertension in the Elderly
Lindon M H Wing,Christopher M. Reid,Philip Ryan,Lawrence J. Beilin,Mark Brown,Garry L. Jennings,Colin I. Johnston,John J McNeil,Graham J. Macdonald,John Marley,Trefor Morgan,Malcolm J. West +11 more
TL;DR: Initiation of antihypertensive treatment involving ACE inhibitors in older subjects, particularly men, appears to lead to better outcomes than treatment with diuretic agents, despite similar reductions of blood pressure.
References
More filters
Journal ArticleDOI
Microalbuminuria Predicts Clinical Proteinuria and Early Mortality in Maturity-Onset Diabetes
TL;DR: It is concluded that microalbuminuria in patients with Type II diabetes is predictive of clinical proteinuria and increased mortality.
Journal ArticleDOI
Predicting Diabetic Nephropathy in Insulin-Dependent Patients
TL;DR: It is concluded that microalbuminuria predicts the development of diabetic nephropathy and that elevated glomerular filtration rates and increased blood pressure may also contribute to this progression.
Journal ArticleDOI
Structural-functional relationships in diabetic nephropathy.
S. M. Mauer,Michael W. Steffes,Eileen N. Ellis,David E.R. Sutherland,David M. Brown,Frederick C. Goetz +5 more
TL;DR: All light and electron microscopic measures of mesangial expansion were strongly related to the clinical manifestations of diabetic nephropathy, although in the absence of these clinical findings, it was not possible to predict the severity of any of the diabetic glomerular lesions.
Journal ArticleDOI
Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.
TL;DR: Prevention of glomerular capillary hypertension in rats with diabetes mellitus effectively protects against the subsequent development ofglomerular structural injury and proteinuria, further supporting the view that hemodynamic rather than metabolic factors predominate in the pathogenesis of diabetic glomerulopathy.
Journal ArticleDOI
Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.
TL;DR: Control of systemic blood pressure is insufficient to prevent progressive renal injury in rats with reduced renal mass, and failure of triple drug therapy to control glomerular hypertension was associated with progressive proteinuria and glomersular lesions comparable to those seen in untreated group 4 rats.